Coronary stenting versus balloon angioplasty in small vessels A meta-analysis from 11 randomized studies by Moreno, Raúl et al.
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OBJECTIVES A meta-analysis of 11 randomized trials was done to compare stenting versus balloon
angioplasty (BA) in small coronary vessels.
BACKGROUND Randomized studies on coronary stenting (CS) in small vessels have yielded controversial
results.
METHODS Eleven randomized trials on CS versus BA in small vessels, including angiographic
re-evaluation at six months, were analyzed.
RESULTS The BeStent (Medtronic Instent, Minneapolis, Minnesota) was used in four studies, the
Multi-Link (Guidant, Advanced Cardiovascular Systems Inc., Santa Clara, California) in
three trials, and the NIR (Boston Scientific Corp., Boston, Massachusetts), JoStent (Jomed
International AB, Helsingborg, Sweden), Tenax (Biotronik, Berlin, Germany), and Bio-
Divysio (Abbott Vascular Devices, Redwood City, California) in the remaining four trials.
Overall, 3,541 patients were included (1,672 allocated to BA and 1,869 to stent). The rate of
cross-over from balloon to stent in the pooled population was 19%, and unsuccessful stent
deployment occurred in 2% of the patients allocated to stent. The pooled rates of restenosis
were 25.8% and 34.2% in patients allocated to stent and balloon, respectively (p 0.003) (risk
ratio [RR] 0.77; 95% confidence interval [CI] 0.65 to 0.92). A smaller reference vessel
diameter at baseline was associated with a higher risk reduction in the restenosis rate (y 
3.551  1.826 [x]; p  0.012). Patients allocated to stent had lower rates of major adverse
cardiac events (15.0% vs. 21.8%, p  0.002; RR 0.70; 95% CI 0.57 to 0.87) and new target
vessel revascularizations (12.5% vs. 17.0%, p  0.004; RR 0.75, 95% CI 0.61 to 0.91).
CONCLUSIONS Elective stenting is superior to provisional stenting in small coronary arteries. This benefit is
more evident in smaller coronary arteries. (J Am Coll Cardiol 2004;43:1964–72) © 2004 by
the American College of Cardiology FoundationM
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woronary stenting (CS) represents the dominant percuta-
eous coronary intervention modality as it significantly
educes the restenosis rate when compared with balloon
ngioplasty (BA). Such benefit was initially demonstrated in
oronary vessels 3 mm or more in diameter (1–3). However,
estenosis after CS implantation is influenced by vessel size,
nd stent occlusion is more frequent in small vessels (4),
eading to a strong controversy on the adequacy of CS in
mall vessels (3 mm). This issue has been addressed by
everal non-randomized (5,6) and randomized (7–18) stud-
es in which CS and BA were compared in this setting,
ielding controversial results.
The objective of this study was to carry out a meta-
nalysis of all available randomized trials comparing CS or
A and small vessels with angiographic re-evaluation at six
onths and to compare the relative effect of these two
reatment strategies on the restenosis rate and clinical
utcome.
From the Division of Interventional Cardiology, Instituto Cardiovascular, Hospital
lı´nico San Carlos, Madrid, Spain.
Manuscript received December 12, 2003; revised manuscript received January 9,6004, accepted January 13, 2004.ETHODS
rial search strategy and eligibility criteria. Twelve ran-
omized studies comparing BA and CS in small (3 mm
eference diameter) vessels, including angiographic re-
valuation at six months, were identified after conducting a
omputerized bibliographic search of the MEDLINE da-
abase and in the abstract supplements of four major
cientific meetings—European Society of Cardiology,
merican College of Cardiology, American Heart Associ-
tion, and Transcatheter Cardiovascular Therapeutics—
ntil July 2003. The entries used in the search were the
ords “stent,” “small vessel,” and “randomized.” Eligible
rials did not include additional modalities of treatment
uch as rotational atherectomy or cutting balloon.
These 12 studies included 3,669 patients. One of the
tudies, the CORDIS Mini-crown stent In small Coronary
rteries (CORDIS-MICA) or Stent Restenosis Study
STRESS) IV trial, was designed to include 600 patients.
owever, it was prematurely interrupted owing to a very
ow inclusion rate and finally included only 128 patients.
ngiographic re-evaluation was performed only in patients
ith recurrent symptoms, whereas the restenosis rates were
3% and 61% in those allocated to BA and CS, respectively.
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June 2, 2004:1964–72 Coronary Stenting in Small Vesselshis study was not included in the meta-analysis, thus the
nal number of patients was 3,541. Of them, 1,672 were
llocated to BA and 1,869 to CS.
Table 1 shows the study design followed in each trial, the
umber of patients allocated to each arm of treatment, the
ype of stent used, and their vessel size inclusion criteria. All
rials were randomized, and most of them were multicenter.
ix were performed in Europe, four in Asia, and one in
atin America.
The BeStent (Medtronic InStent, Minneapolis, Minne-
ota) was used in the BEstent in SMall ARTeries (BES-
ART), Restenosis en Arterias Pequen˜as (RAP), Stenting
n Small Arteries (SISA), and Stenting In Small Coronary
rteries (SISCA) trials. In the RAP and BESMART trials,
Abbreviations and Acronyms
BA  balloon angioplasty
BESMART  BEstent in SMall ARTeries
CHIVAS  Coronary Heart Disease Stenting In
Small Vessels Versus Balloon
Angioplasty Study
CI  confidence interval
COAST  heparin-COAted STents in small
coronary arteries
COMPASS  Cilostazol Or Multi-link for
Percutaneous transluminal coronary
Angioplasty Small vessel Study
CS  coronary stenting
ISAR-SMART  Intracoronary Stenting or
Angioplasty for Restenosis
Reduction in Small Arteries
ISAR-STEREO  Strut Thickness Effect on Restenosis
Outcome
LASMAL  Latin America Small Vessel
Randomized Study
MLD  minimum lumen diameter
RAP  Restenosis en Arterias Pequen˜as
RR  risk ratio
RVD  reference vessel diameter
SISA  Stenting In Small Arteries
SISCA  Stent In Small Coronary Arteries
STRESS  Stent Restenosis Study
able 1. Characteristics of the Studies Included in the Meta-Ana
Study (Reference) Country Design
No.
Patie
BA
ark et al. (7) Korea Single-center 60
SAR-SMART (8) Germany Multicenter 200
ISCA (9) Norway/Sweden Multicenter 71
ESMART (10) France Multicenter 189
ISA (11) Japan Single-center 182
OAST (12) Europe Multicenter 195
AP (13) Spain Multicenter 214
ASMAL-I (14) Latin America Multicenter 122
VS (15) The Netherlands Multicenter 246
HIVAS (16) Japan Multicenter 143
OMPASS (17) Japan Single-center 50A  balloon angioplasty; CS  coronary stenting.nly a premounted 15-mm BeStent was used, but in the
ISA study, 8-mm and 25-mm unmounted BeStents were
llowed. In the SISCA trial, a heparin-coated version
Hepamed, Medtronic Bakker Research Center, Maas-
richt, the Netherlands), developed exclusively for this trial,
as used. The Multi-Link stent (Guidant, Advanced Car-
iovascular Systems Inc., Santa Clara, California) was used
n the Intracoronary Stenting or Angioplasty for Restenosis
eduction in Small Arteries (ISAR-SMART), Coronary
eart Disease Stenting In Small Vessels Versus Balloon
ngioplasty Study (CHIVAS), and Cilostazol Or Multi-
ink for Percutaneous transluminal coronary Angioplasty
mall vessel Study (COMPASS) trials. In the study by Park
t al. (7), the NIR stent (Boston Scientific Corp., Boston,
assachusetts) was used. In the COAST (heparin-
OAted STents in small coronary arteries) trial, patients
ere randomized to BA, implantation of a bare JoStent Flex
tent (JOMED International AB, Helsingborg, Sweden), or
heparin-coated JoStent Flex stent (JOMED International
B), available in 9, 16, and 26 mm. In the Small Vessel
tudy (SVS), a silicon carbide coating Tenax stent
Biotronik, Berlin, Germany) was used, and in the Latin
merica Small Vessel Randomized Study (LASMAL),
atients were randomized to BioDivysio stent (Abbott
ascular Devices, Redwood City, California) or BA. Strut
hickness varied from 50 m (Multi-Link) to 101 m
BioDivysio).
Cross-over from BA to CS was allowed in two circum-
tances: 1) as a bail-out procedure in the case of abrupt or
hreatened closure caused by a coronary dissection with
ompromised antegrade blood flow; and/or 2) in the case of
suboptimal result defined by a residual stenosis 50% in
ost studies, and 30% in the ISAR-SMART and in the
tudy by Park et al. (7). Cross-over from CS to BA was
odified as failure to deliver the stent. In the CHIVAS
tudy, patients requiring cross-over were excluded from the
tudy.
Most studies used CS after balloon predilation, although
n some of them direct stent implantation was allowed.
Inclusion
Criteria
(mm)
Re-Evaluation
(%) Type of Stent
Strut
Thickness
(m)
 3 92.5 NIR 100
2.0–2.8 82.7 Multi-Link 50
2.1–3.0 97.2 Hepamed-coated 85
 3.0 85.3 BeStent 85
2.3–2.9 81.2 BeStent 85
2.0–2.6 79.9 JoStent  coated 90
2.2–2.7 81.9 BeStent 85
2.0–2.9 87.8 BioDivisyo 101
2.0–3.0 71.6 Tenax 80
 3.0 80.3 Multi-Link 50
 3.0 93.0 Multi-Link 50lysis
of
nts
CS
60
204
74
192
169
393
212
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250
141
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Coronary Stenting in Small Vessels June 2, 2004:1964–72All patients received heparin and aspirin, although in the
OMPASS trial, patients treated with BA received cilosta-
ol instead of aspirin. Those treated with CS also received
iclopidine or clopidogrel for one month. In the ISAR-
MART, all patients received abciximab (8). In most
tudies, however, glycoprotein IIb/IIIa inhibitors were not
sed (10), were discouraged and allowed only when neces-
ary (11,12), or were used as local standards (9) or according
o the physician’s preference (14,15).
ngiographic analysis and definitions. Quantitative cor-
nary analysis was performed using the CMS 4.0, 4.1, or 5.0
Medis, Leiden, the Netherlands) edge-detection system in
ost studies. Intracoronary nitroglycerin was given before
ach angiography, and the contrast-filled catheter was used
or calibration.
“Acute gain” was the difference in minimum lumen
iameter (MLD) between post-intervention and baseline.
Late loss” was the difference in MLD between post-
ntervention and follow-up. “Net gain” was the difference in
LD between follow-up and baseline. “Loss index” was
alculated by dividing late lumen loss by short-term gain.
Angiographic restenosis” was binarily defined as 50%
iameter stenosis at follow-up.
The diagnosis of myocardial infarction was based on the
resence of new pathologic Q waves and/or a value of
reatine kinase level or its myocardial band of at least twice
9–14) or three times (7,8) the upper normal limit. Target
essel revascularization was performed in the presence of
ngiographic restenosis associated with angina or ischemia
emonstrated by non-invasive studies.
tatistical analysis. The review was conducted according
o the Quality of Reports of Meta-Analyses of Randomized
linical Trials (QUOROM) recommendations (19). The
eview Manager 4.1.1 (Cochrane Collaboration, Oxford,
nited Kingdom) and the SPSS 10.0 (SPSS Inc., Chicago,
llinois) statistical packages were used.
Quantitative variables are expressed as mean  standard
eviation, and discrete variables as proportions (percent-
ges). Associations between categorical variables were stud-
able 2. Treated Vessel and Prevalence of Diabetes Mellitus in P
Study (Reference)
BA
LAD RCA LCX Other
ark et al. (7) 55 15 30 —
SAR-SMART (8) 40 20 40 —
ISCA (9) 39 17 44 —
ESMART (10) 37 13 41 9
ISA (11) 47 20 33 —
OAST (12) 41 22 37 —
AP (13) NA NA NA NA
ASMAL-I (14) 48 15 30 7
VS (15) 43 20 36 1
HIVAS (16) NA NA NA NA
OMPASS (17) NA NA NA NA
p  0.05.
LAD  left anterior descending; LCX  left circumflex; NA  non-available; Red by the chi-square test (Fisher correction in case any cxpected value was 5). The risk ratio (RR) for restenosis
nd late (6-month) clinical events, the absolute risk reduc-
ion, and their 95% confidence intervals (CI) were calcu-
ated comparing CS rates with BA rates using raw data for
ach study and for the pooled population. Inter-trial heter-
geneity was calculated with the Q-test, and the Der
imonian and Laird’s random effects model was used to
stimate the combined effect weighting by the inverse
ariance estimated. The number of patients required to be
reated with CS to prevent one restenosis was calculated as
he inverse of the absolute risk reduction.
The primary objective was to evaluate the restenosis rate at
ix months in patients allocated to BA or CS on an intention-
o-treat basis. Clinical outcomes for comparison were death,
yocardial infarction, target lesion revascularization, and ma-
or adverse cardiac events at six months (the occurrence of at
east one of the clinical end points listed previously).
The association between the benefit of CS in each study
nd continuous variables was evaluated by lineal regression
nalysis, calculating a and b coefficients. Statistical signifi-
ance was considered in the presence of p  0.05.
ESULTS
mmediate angiographic results. No significant differ-
nces were found according to target vessel and allocated
reatment (Table 2). The reference vessel diameter (RVD)
t baseline was similar in patients allocated to BA and CS
nd ranged from 2.24 to 2.60 mm in BA (mean 2.35 mm in
he pooled population) and from 2.23 to 2.59 mm in CS
mean 2.36 mm in the pooled population) (Table 3).
The rate of cross-over in patients allocated to BA but finally
equiring CS implantation ranged from 6% to 28% (19% in the
ooled population), and the proportion of patients allocated to
S in which the stent could not be finally implanted ranged
rom 0% to 6% (2% in the pooled population).
Balloon/vessel ratio was 1.1 for both the BA and CS
roups, without significant differences between both strat-
gies. However, final pressure was higher in patients allo-
ts Treated With Balloon or Stent
CS Diabetes
LAD RCA LCX Other BA CS
45 22 33 — 12 13
42 20 38 — 25 25
38 16 46 — 14 12
39 10 44 8 12 22*
43 23 34 — 21 18
40 18 42 — 17 20
NA NA NA NA 37 30
47 18 33 2 25 28
39 19 41 1 16 17
NA NA NA NA 31 33
NA NA NA NA NA NA
right coronary artery; other abbreviations as in Table 1.atien
CA ated to CS. In all studies, immediate results were better in
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June 2, 2004:1964–72 Coronary Stenting in Small Vesselshe CS group, achieving higher short-term gain and larger
LD (Table 3).
ngiographic follow-up. The rate of angiographic re-
valuation ranged from 71.6% to 97.2% (82.1% in the
ooled population) (Table 1). Patients allocated to CS had
igher late loss and loss index, but as a result of a
ignificantly higher short-term gain, net gain was higher in
hese patients. Only in the BESMART, RAP, and CHI-
AS trials differences in the restenosis rate reached statis-
ical significance (Table 4) (Fig. 1).
The pooled restenosis rate was 25.8% (413 of 1601) and
4.2% (471 of 1,376) in patients allocated to CS and BA,
espectively (p  0.003; RR 0.77; 95% CI 0.65 to 0.92)
absolute risk reduction 0.07, 95% CI 0.02 to 0.13, p 
.005). Thus, 12 patients (95% CI 9 to 20) would be needed
o treat with CS to prevent a restenosis.
actors related to risk reduction in restenosis. The risk
eduction of restenosis had a significant relationship with
hort-term gain in the BA group (y  0.218  0.506 [x]; p
0.039) and a significant relationship with MLD post-
able 3. Immediate Angiographic Results
Study (Reference)
Cross-
Over RVD Length
BA CS BA CS BA CS
ark et al. (7) 20 0† 2.48 2.55 NA NA
SAR-SMART (8) 17 4† 2.37 2.41 11.8 12.5
ISCA (9) 14 4† 2.38 2.44 10.8 11.8
ESMART (10) 23 3† 2.24 2.23 9.6 9.1
ISA (11) 21 1† 2.45 2.50 10.2 10.8
OAST (12) 27 2† 2.32 2.32 7.7 7.6
AP (13) 14 2† 2.29 2.32 8.3 9.2
ASMAL-I (14) 18 0† 2.48 2.46 NA NA
VS (15) 28 6† 2.27 2.30 NA NA
HIVAS (16) 8‡ 0† 2.35 2.39 11.1 11.2
OMPASS (17) 6 0 2.60 2.59 NA NA
verall 19 2† 2.35 2.36 9.9 9.8
p 0.05. †p 0.01. ‡In the CHIVAS trial, patients requiring cross-over from balloo
as 0%.
MLD  minimum lumen diameter; RVD  reference vessel diameter; other abb
able 4. Angiographic Follow-Up
Study (Reference)
Restenosis (%) Late
BA CS BA
ark et al. (7) 30.9 35.7 0.63
SAR-SMART (8) 37.4 35.7 0.72
ISCA (9) 18.8 9.7 0.25
ESMART (10) 47 21† 0.57
ISA (11) 32.9 28.0 0.48
OAST (12) 32.2 27.2 0.73
AP (13) 37 27* 0.55
ASMAL-I (14) 29 19 0.57
VS (15) 25.3 21.2 0.35
HIVAS (16) 43.5 30.8* NA
OMPASS (17) 17.6 25.0 0.22
verall 34.2 25.8 0.54
p  0.05. †p  0.01.
Abbreviations as in Tables 1 and 2.ntervention (y  1.043  0.821 [x]; p  0.023), late loss
y  0.083  0.957 [x]; p  0.018), and loss index (y 
0.103  1.686 [x]; p  0.046) in the CS group.
mportantly, a smaller RVD at baseline was associated with
igher risk reduction of restenosis (y3.551 1.826 [x];
 0.012) (Table 5) (Fig. 2). This was because a smaller
VD was associated with higher restenosis rate in patients
llocated to BA (y  148.421  48.838 [x]; p  0.065) but
ot to CS (y  6.490  13.266 [x]; p  0.566).
There was no significant association between risk reduc-
ion of restenosis and other variables such as strut thickness
r the proportion of patients with angiographic re-
valuation (Table 5).
linical events at six months. The pooled rate of major
dverse cardiac events was significantly lower in patients
llocated to CS (15.0% vs. 21.8%, p 0.002; RR 0.70, 95%
I 0.57 to 0.87) (Fig. 3) (Table 6). (absolute risk reduction
.06, 95% CI 0.02 to 0.10, p 0.041). This was mainly due
o a reduction in the need for new revascularization proce-
ures (Fig. 4). The proportion of patients requiring new
Acute Gain Final MLD Balloon/Vessel
Pressure
(atm)
BA CS BA CS BA CS BA CS
1.49 1.85† 2.14 2.44† 1.08 1.10 12.9 13.3
1.47 1.77† 1.98 2.35† 1.06 1.13† 12.0 13.5†
0.77 1.23† 1.79 2.22† 1.06 1.04 10.6 13.3†
0.94 1.35† 1.70 2.06† 1.02 1.05 10.2 10.5
0.91 1.37† 1.85 2.31† 1.03 1.08* 10.5 11.7†
1.24 1.42† 2.05 2.18† 1.11 1.09 12.0 14.0†
1.04 1.55† 1.84 2.33† NA NA NA NA
1.35 1.51† 2.10 2.30† NA NA NA NA
0.92 1.08† 2.37 2.49† NA NA NA NA
0.82 1.08† 1.56 1.78† NA NA NA NA
NA NA 2.10 2.63 NA NA NA NA
1.08 1.41† 1.96 2.26† 1.06 1.09 11.4 13.3
ent were excluded from the study, and thus the cross-over rate in the study population
ions as in Tables 1 and 2.
(mm) Net Gain (mm) Loss Index (mm)
CS BA CS BA CS
1.12† 0.86 0.75 0.45 0.61*
1.04† 0.76 0.76 0.44 0.59†
0.54† 0.55 0.72* 0.32 0.44†
0.65† 0.43 0.72† 0.56 0.46
0.89† 0.43 0.51 0.46 0.67*
0.73† 0.55 0.70* 0.61 0.52
0.86† 0.49 0.69 0.53 0.55
0.60 0.74 1.07† 0.42 0.40
0.51† 0.57 0.58 0.38 0.47*
NA NA NA NA NA
0.99† NA NA NA NA
0.76 0.57 0.71 0.48 0.52n to st
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Coronary Stenting in Small Vessels June 2, 2004:1964–72evascularization procedures of the treated vessel was sig-
ificantly lower among those allocated to CS (12.5% vs.
7.0%, p  0.004; RR 0.75, 95% CI 0.61 to 0.91) (absolute
isk reduction 0.04, 95% CI 0.01 to 0.7, p  0.01).
The pooled rate of death was low in patients allocated to
ither CS or BA (0.7% vs. 1.2%, respectively, p  0.2; RR
.61; 95% CI 0.27 to 1.35). The proportion of patients
uffering myocardial infarction was nonsignificantly lower in
hose allocated to CS (2.7% vs. 4.3%, p  0.12; RR 0.74,
5% CI 0.50 to 1.09).
ISCUSSION
ffect of coronary stents on restenosis rate in small
essels. The RVD is an important parameter that is taken
nto account when considering whether or not to implant a
oronary stent, those vessels with smaller RVD being
igure 1. Effect of coronary stenting (CS) on restenosis rate at six month
5% confidence intervals (CI). See Abbreviation Box for trial acronym de
able 5. Relationship Between the Risk Reduction in
estenosis and Angiographic Variables
Lineal Regression Equation p Value
trut thickness y  0.811  0.104 [x] 0.654
LD post-BA y  0.415  0.638 [x] 0.091
cute gain BA y  0.218  0.506 [x] 0.039
ate loss BA y  0.941  0.195 [x] 0.737
et gain BA y  0.241  0.900 [x] 0.069
oss index BA y  0.766  0.028 [x] 0.976
LD post-CS y  1.043  0.821 [x] 0.023
cute gain CS y  0.117  0.461 [x] 0.082
ate loss CS y  0.083  0.957 [x] 0.018
et gain CS y  0.943  0.228 [x] 0.681
oss index CS y  0.103  1.686 [x] 0.042
ross-over BA to CS y  0.932  0.006 [x] 0.592
asal RVD y  3.551  1.826 [x] 0.012
esion length y  0.618  0.010 [x] 0.852
diabetics y  0.913  0.007 [x] 0.377
angio. evaluation y  0.345  0.006 [x] 0.656bbreviations as in Tables 1 and 3. Breated with CS less frequently than larger vessels (20).
maller RVD are associated with higher restenosis rates
fter CS implantation (21), and this association has been
ited in support of a restrictive use of CS in small vessels.
he main explanation for this worse angiographic and
linical outcome in smaller vessels after CS is the relatively
imilar late loss irrespective of stent diameter and, thus, the
igher loss index in smaller coronary arteries (22). However,
mall vessel size is an independent risk factor for the
evelopment of restenosis also after BA (23). It is contro-
ersial whether stents should be used as primary therapy for
mall vessels. Coronary stenting allows a more aggressive
alloon dilation strategy leading to improved results with
A, although requiring CS implantation when a significant
each study and in the pooled population, showing risk ratio (RR) and its
ns.
igure 2. Association between reference vessel diameter (RVD) and risk
atio (RR) for restenosis in each study (lineal regression). See Abbreviations forox for trial acronym definitions.
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June 2, 2004:1964–72 Coronary Stenting in Small Vesselsoronary dissection is produced or when a suboptimal result
s obtained with BA.
Studies comparing provisional versus elective stenting in
mall coronary arteries have yielded contradictory results. Of
he 11 studies included in the present meta-analysis, eight
howed no significant differences in the rate of restenosis
etween patients allocated to BA or CS. Differences were
tatistically significant only for the BESMART, RAP, and
HIVAS trials. Probably, the number of patients was too
ow in some of these studies, taking into consideration two
acts. First, there was a relatively high rate of cross-over
rom BA to CS (20%), higher than that reported in the
TRESS and BElgian Netherlands STENT (BENEST-
NT) studies (6.9% and 5.1%, respectively). Second, the
bsolute reduction in restenosis rate in small vessels (8.4%)
eems to be lower than in 3-mm vessels (10% to 15%)
1–3). In some trials on CS in small vessels, the number of
atients was calculated assuming a 15% to 20% absolute
eduction in restenosis rate and a lower rate of cross-over
rom balloon to stent (7,8,14).
In the pooled analysis, restenosis significantly decreased
rom 34.2% to 25.8% (8.4% absolute reduction). This
eduction is lower than that reported for 3-mm vessels
10% to 15%) (1–3), probably owing to the relatively similar
ate loss after CS irrespective of stent diameter, thus CS
resenting a higher loss index in small vessels (23). The
igher cross-over rate from BA to CS in small vessels
20%, in comparison with 5% to 7% in 3-mm vessels)
robably reflects the poorer angiographic results of BA in
mall vessels.
The explanation for the benefit of CS in small vessels was
he better initial angiographic results (higher short-term
ain and MLD post-procedure) for CS, despite the higher
ate loss observed in patients allocated to this treatment.
The reduction in restenosis in patients allocated to CS
igure 3. Effect of coronary stenting (CS) on the rate of cardiac events at s
nd its 95% confidence intervals (CI). See Abbreviation Box for trial acroas reflected in an improvement in the outcome, especially recause of a significant reduction in the need for new
evascularization procedures.
easons for discrepancies between different studies and
ssociated characteristics. Differences in immediate results
f patients allocated to BA may be the main reason explaining
iscrepancies among studies. Higher short-term gain in pa-
ients allocated to BA, as well as higher late loss in patients
llocated to CS, were associated with lower risk reductions.
Importantly, there was a significant association between
VD and the benefit of CS in reducing the restenosis rate:
smaller RVD, a lower RR for restenosis (higher risk
eduction). In the BESMART trial, although the benefit of
tenting in reducing restenosis was not statistically associ-
ted with RVD, the higher risk reduction was obtained in
essels 1.5 to 1.9 mm (70%, in comparison with 56% and
0% in vessels 2.0 to 2.4 mm and 2.5 to 2.9 mm,
espectively). Probably, smaller RVD is associated with
orse immediate angiographic results of BA, and the
eleterious effect of smaller RVD on the midterm results of
ercutaneous coronary interventions could be more impor-
ant in patients treated with BA. A post hoc analysis of the
TRESS trial, showing that benefit of CS was more evident
n 3-mm vessels, compared with larger coronary arteries,
upports this hypothesis (24). Similar data were provided by
he STent versus Angioplasty Restenosis Trial (START), in
hich restenosis decreased from 32% to 22% in 3-mm
essels, and from 45% to 25% in 3-mm vessels (3).
In a subanalysis of the CHIVAS study, it was shown that
he effect of CS in reducing restenosis in small vessels may
e particularly evident in diabetic patients (25). We did not
nd, however, any significant correlation between the pro-
ortion of diabetic patients and the risk reduction. In the
ngoing LASMAL-II trial, 188 diabetic patients with small
essels have been randomized to CS or BA. Angiographic
ollow-up of this trial is pending.
Stent design or type did not influence the effect of CS in
nths for each study and in the pooled population, showing risk ratio (RR)
definitions.ix moestenosis. In the Strut Thickness Effect on Restenosis
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Coronary Stenting in Small Vessels June 2, 2004:1964–72utcome (ISAR-STEREO-2) trial, patients treated with
hin-strut (50-m) stents had lower restenosis rate than
hose receiving 140-m strut stents (26). Nevertheless, we
id not find any significant association between strut thick-
ess and risk reduction. This could be because differences
mong strut thickness of the stents used in the trials
ncluded in the meta-analysis were lower in comparison
ith the ISAR-STEREO-2 trial. In fact, in one study by a
roup in Milan, struts were considered thin and thick at
100 m and 100 m, respectively (27), and according
o this criterion, only the stents used in the LASMAL-I
rial and the study by Park et al. (7) could be considered to
ave thick struts. Finally, the use of heparin-coated stents
id not confer any advantage over bare metal stents, as
bserved in the SISCA and COAST trials.
Drug-eluting stents can dramatically reduce the resteno-
is rate, and they constitute a recent revolution in interven-
ional cardiology (28). However, we have to consider two
mportant points. First, small vessels, although having a
able 6. Clinical Events
Death (%) AM
BA CS BA
ark et al. (7) 0 0 3.3
SAR-SMART (8) 1.5 1.0 3.0
ISCA (9) 0 1.4 1.4
ESMART (10) 2.4 0.6 6.6
ISA (11) 0.5 0.6 8.2
OAST (12) 0 1.0 0.0
AP (13) 1.4 0.5 1.4
ASMAL-I (14) 3.2 0.8 9.0
VS (15) 0.4 0.9 3.9
HIVAS (16) 2.7 0 NA
OMPASS (17) 0 0 0
verall 1.2 0.7 4.0
p  0.05; †p  0.01.
AMI  acute myocardial infarction; MACE  major adverse cardiac events; TV
igure 4. Effect of coronary stenting (CS) on the rate of new revasculari
howing risk ratio (RR) and its 95% confidence intervals (CI). See Abbreviatioigher rate of angiographic restenosis, undergo subsequent
ew revascularization procedures less frequently, owing to
he smaller amount of myocardium supplied by the vessel.
econd, some recent data from the SIRIUS trial (Sirolimus-
luting Stents versus Standard Stents in patients with
tenosis in a native coronary artery) demonstrate that the
estenosis risk reduction decreases as RVD decreases (29).
n that study, the restenosis rate for sirolimus-eluting stent
nd bare metal stent, respectively, was 30.2% vs. 1.9%
93.7% risk reduction), 36.5% vs. 6.3% (82.7% risk reduc-
ion), and 42.9% vs. 18.6% (56.6% risk reduction) for vessels
veraging 3.3 mm, 2.8 mm, and 2.3 mm in RVD, respec-
ively (4, 3, and 4 patients needed to treat with sirolimus-
luting stent to prevent a restenosis, respectively). Because
f all these findings, many interventional cardiologists
elieve that the clinical benefit, and thus the cost/
ffectiveness, of drug-eluting stents in small vessels may be
ess favorable than in larger vessels. However, the recently
vailable data from the TAXUS-IV trial show a greater
TVR (%) MACE (%)
CS BA CS BA CS
1.7 5.0 3.3 8.3 5.0
3.4 16.5 20.1 19.0 23.0
1.4 22.5 9.5* 23.9 9.5*
5.1 27.1 15.3† 33.7 18.8†
4.1 20.3 17.8 22.0 18.3
0.5 14.4 10.7 15.4 11.7
0.9 22.3 12.2* 25.1 13.6*
5.6 19.7 14.5 27.0 16.9
3.9 5.6 6.0 10.4 13.4
NA 15.5 11.2 18.2 11.2
0 NA NA NA NA
2.7* 17.0 12.5† 20.4 14.8†
target vessel revascularization; other abbreviations as in Table 1.
procedures at six months for each study and in the pooled population,I (%)
R zation
n Box for trial acronym definitions.
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June 2, 2004:1964–72 Coronary Stenting in Small Vesselsenefit of paclitaxel-eluting stent in small vessels. In that
tudy, the restenosis rate was 15.2% vs. 6.8% (55.3% risk
eduction), 27.8% vs. 6.7% (75.9% risk reduction), and
8.5% vs. 10.2% (73.5% risk reduction) for vessels 3.0
m, 2.5 to 3.0 mm, and 2.5 mm in RVD, respectively
30) (12, 5, and 4 patients needed to treat with paclitaxel-
luting stent to prevent a restenosis, respectively). It could
e speculated that an increasing dose of paclitaxel per unit
essel surface area could partly explain this greater benefit of
aclitaxel-eluting stent in small vessels.
The demonstration from this meta-analysis that the bare
etal stent is a better treatment than BA for small vessels
rovides an important basis for future trials of drug-eluting
tents in small vessels. Before the demonstration that
rug-eluting stents are a better treatment for small vessels
han bare metal stents, we have previously had the security
hat bare metal stents are better than BA for these vessels. In
his meta-analysis, we have demonstrated that bare metal
tents are not only of angiographic benefit (lower restenosis
ate) but also of clinical benefit (lower rate of repeat
evascularization procedures).
tudy limitations. As in other meta-analyses, the present
ne has the inherent limitations of heterogeneity in inclu-
ion criteria and definitions of outcomes. Also, the conclu-
ions are not applicable to patients not fulfilling the inclu-
ion criteria of these studies. In particular, lesion length was
elatively short (10 mm), and the benefit of CS over BA
n longer lesions is not necessarily the same as shown in
hese trials. Second, data on restenosis rate were given as
ummary data, as provided from the trials included. Finally,
ost trials included in the meta-analysis used CS after
redilation. Recently, the PIXEL trial demonstrated that
he restenosis rate after CS in small vessels is lower when a
o-predilation versus a predilation implantation strategy is
sed (31).
onclusions. Coronary stenting reduces the restenosis rate
n small vessels, which translates into fewer major adverse
ardiac outcomes mainly because it reduces the need for new
evascularization procedures. This benefit seems to be espe-
ially evident with smaller RVD.
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